Clinical trial
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
NCT00494299 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
- Lead sponsor
- Bayer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2006
- Completion date
- November 30, 2010
- Enrollment
- 458 (actual)
- Sites
- 75
Conditions
As the registry lists them; a condition with its own page is linked.